Shares of Sellas Life Sciences surged 7.1% to $14.70 on August 27 after an unconfirmed report — originating from a German source — claimed the company's pivotal REGAL leukemia trial had reached its 80th event . That threshold matters enormously: the 80th event (death) is the pre-specified trigger for the final analysis of an overall survival study . If the data show the drug works, Sellas could pursue FDA approval in a market with few maintenance options for relapsed leukemia patients. If not, the stock faces a cliff.

  • The Official Count Is Still Two Deaths Short. Sellas's August 11 Q2 update confirmed the trial was still "approaching" the 80th event, with the last official count remaining at 78 of 80 as of May 11 . On August 18, Chinese licensing partner 3D Medicines separately told the Hong Kong Stock Exchange the global trial had accumulated 78 events — and neither party has announced event 80, database lock, unblinding, or topline results . Investors are pricing in a milestone the company itself has not confirmed.

  • Even Hitting 80 Doesn't Mean Instant Answers. Sellas must first complete a database lock, blinded review, statistical analysis, and unblinding process before topline data are released . That means weeks or months could separate the 80th event from the moment shareholders learn whether the drug actually extended survival. Trading on the rumor buys exposure to the catalyst but not to the result.

  • Wall Street Is Betting Big — With Eyes Wide Open. Two analysts polled by S&P Global give SLS a consensus "Buy" with an average price target of $32.50, implying over 100% upside, with targets ranging from $30 to $35 . Alliance Global raised its target to $35 from $25 on August 17 . But the bull case hinges entirely on a positive trial outcome. Sellas posted a Q2 net loss of $9.61 million and a first-half loss of $18.01 million — it has no approved products and no revenue.

  • Cash Buys Time, but Dilution Has Already Arrived. Cash stood at $138.3 million as of June 30 , providing a multi-year runway. Yet the share count roughly doubled year-over-year, from 87.8 million weighted-average shares in Q1 2025 to 172.5 million in Q1 2026 . Existing shareholders absorbed heavy dilution to fund this moment. A failed readout would make that sacrifice permanent; a successful one could justify it many times over.

This is, ultimately, a binary bet dressed up in a rumor. Until Sellas issues an official press release confirming event 80, today's pop is sentiment, not substance.